Dirlotapide

Dirlotapide is a drug used to treat obesity in dogs.^[1] It is manufactured by Pfizer and Zoetis and marketed under the brand name Slentrol.^{[citation needed]}

Dirlotapide

Clinical data
Trade names	Slentrol
AHFS/Drugs.com	International Drug Names
Routes of administration	By mouth
ATCvet code	QA08AB91 (WHO)
Legal status
Legal status	CA: ℞-only US: ℞-only
Pharmacokinetic data
Protein binding	High[1]
Metabolism	Liver
Elimination half-life	5–18 hours (increased with repeated dosing)
Excretion	Feces, urine
Identifiers
IUPAC name 1-Methyl-N-[(1S)-2-(methyl-(phenylmethyl)amino)-2-oxo-1-phenylethyl]-5-[[oxo-[2-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]-2-indolecarboxamide
CAS Number	481658-94-0 Y
PubChem CID	9917862
ChemSpider	8093509 Y
UNII	578H0RMP25
KEGG	D03867 Y
ChEMBL	ChEMBL410414 Y
CompTox Dashboard (EPA)	DTXSID00897432
Chemical and physical data
Formula	C40H33F3N4O3
Molar mass	674.724 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c1ccc(cc1)c2ccccc2C(=O)Nc3cc4c(cc3)n(c(c4)C(=O)N[C@@H](c5ccccc5)C(=O)N(Cc6ccccc6)C)C
InChI InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1 Y Key:TUOSYWCFRFNJBS-BHVANESWSA-N Y
(verify)

It works as a gut-selective microsomal triglyceride transfer protein (MTTP or MTP) inhibitor.^[2] This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption.^{[medical citation needed]} It also elicits a satiety signal from lipid-filled cells lining the intestine.^{[medical citation needed]}

Usage

It is supplied as an oral solution. It is not intended for use in humans, cats, birds, rodents, or other animals.

Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It is used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma.

Regulation and safety

On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs.^[3][4]

However, concerns have since been raised, since 2010, about adverse effects^[5] that might more strongly affect particular breeds.^[6]

Dirlotapide (under the brand name Slentrol) was authorized for use in the EU by the European Medicines Agency for helping weight loss in dogs, but has since been withdrawn from the market in the EU.^[7]